Table 2.
Clinical Characteristics of Patient Participants
| CT group | RT group | pa | |
|---|---|---|---|
| Time between diagnosis and T1 assessment (months), mean (SD) | 14.12 (2.89) | 9.96 (2.49) | <.001 |
| Surgery (%) | |||
| Lumpectomy | 84 | 99 | .003 |
| Mastectomy | 16 | 1 | |
| Stage (%) | |||
| 0 | 2 | 18 | <.001 |
| I | 27 | 79 | |
| II | 71 | 3 | |
| Hormonal therapy (%) | |||
| No | 52 | 24 | <.001 |
| Yes | 48 | 76 | |
| Tamoxifenb | 40 | 69 | |
| Anastrozole (Arimidex) | 5 | 4 | |
| Toremifene (Fareston) | 0 | 3 | |
| Letrozole (Femera) | 3 | 0 | |
| Radiation | |||
| Number of treatments, mean (SD) | 31.13 (3.92) | 30.33 (4.96) | .318 |
| dose in cGy, mean (SD) | 5985.97 (560.92) | 5921.88 (688.57) | .569 |
| Number of chemotherapy cycles, mean (SD) | 5.57 (1.84) | ||
| Chemotherapy regimens (%) | |||
| Doxorubicin + Cyclophosphamide | 51 | ||
| Doxorubicin + Cyclophosphamide + Taxotere | 13 | ||
| Doxorubicin + Cyclophosphamide + Paclitaxel | 19 | ||
| Cyclophosphamide + Methotrexate + 5FU | 8 | ||
| Doxorubicin + Taxotere | 2 | ||
| Cyclophosphamide + Epirubicin + 5FU | 5 | ||
| Cyclophosphamide + Epirubicin + 5FU + Paclitaxel | 2 | ||
CT group, patients treated with chemotherapy plus radiotherapy; RT group, patients treated with radiotherapy only; NC group, non-cancer participants
a
P-values are based on chi square analyses for categorical variables and one-way analyses of variance for continuous variables.
b
One participant who received both tamoxifen and anastrozole was included in the tamoxifen group.